ArticleClinical, cosmetic and investigational dermatology2026
Clinical Profile of Elderly Atopic Dermatitis in China.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-related changes of FCGR3AEBioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With global population aging, elderly atopic dermatitis (AD) is emerging as a distinct subtype. This study investigated the clinical and hematological phenotype of elderly AD patients in a Chinese cohort. Methods: 593 patients who fulfilled the Chinese Criteria for Atopic Dermatitis (CCAD) were stratified into three age groups: 2-17, 18-59, and ≥ 60 years. Clinical features and risk factors were assessed via a standardized questionnaire and physical examination. Serum total IgE and complete blood counts were measured in a subset of patients along with age-matched healthy controls. Results: Approximately three-quarters of the elderly AD patients were late-onset (first presentation ≥ 60 years old), with male predominance (male-to-female ratio 2.03:1). Lesions displayed a "widespread" distribution pattern in elderly AD. Over 80% of elderly AD patients had moderate-to-severe disease (SCORAD ≥ 25), with greater pruritus, quality-of-life impairment, and worse management outcomes compared with younger groups. The endogenous subtype increased with age, accounting for 47% of elderly AD. The elderly AD had higher monocyte count and percentage but lower lymphocyte count than other age groups. The Eczema Area and Severity Index (EASI) positively correlated with eosinophil count, and negatively with lymphocyte count and percentage in elderly AD. Conclusion: Elderly AD exhibits a distinct clinical and hematological phenotype characterized by severe disease burden, widespread distribution, male predominance, and age-specific immune dysregulation. While the role of eosinophil is established, our findings underscore the need for age-tailored management strategies and highlight the monocyte-macrophage axis as a novel direction for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.